公 司 华福证券 医院 2025 年 05 月 06 日 华厦眼科（301267.SZ） 买入（维持评级） 研 究 25Q1 收入增长稳健，员工持股计划有望增强人 才吸引力 投资要点： 公 司 财 报 点 事件：公司公布 2024 年年报及 2025 年一季报，2024 年公司实现收入 40.3 亿 元（+0.35%），实现归母净利润 4.29 亿元（-35.6%）；2025Q1 公司实现收入 10.93 亿元（+11.7%），实现归母净利润 1.5 亿元（-4%），业绩符合预期。 此外，公司公布设立 2025 年员工持股计划。 分业务：屈光和视光实现稳健增长。 评 分业务看，24 年公司屈光业务实现收入 12.96 亿元（+7.44%），毛利率 52.05% （-2.45pct），视光业务实现收入 10.69 亿元（+5.15%），毛利率 45.57%（-4.49pct）， 白内障业务实现收入 8.73 亿元（-11.56%），毛利率 35.16%（-8.53pct），眼后段 业务实现收入 5.36 亿元（+9.21%），毛利率 39.64%（-4.99pct），其他业务收入 2.53 亿元（-5.63%） ...

Investment Rating - The investment rating for the company is "Buy" [5] Core Insights - The company reported a revenue of 20.983 billion yuan in 2024, reflecting a year-on-year growth of 3.0%, and a net profit attributable to shareholders of 3.556 billion yuan, up 5.9% [1] - The first quarter of 2025 saw a revenue of 6.026 billion yuan, representing a 16.0% increase, and a net profit of 1.050 billion yuan, which is a 16.7% rise [1] - The company is expected to achieve revenues of 23.430 billion yuan and 25.960 billion yuan in 2025 and 2026, respectively, with corresponding growth rates of 11.7% and 10.8% [4] Business Performance - In 2024, the revenue from various business segments was as follows: refractive (7.60 billion yuan, +2.3%), vision care (5.28 billion yuan, +6.4%), cataract (3.49 billion yuan, +4.9%), anterior segment (1.90 billion yuan, +6.0%), and posterior segment (1.50 billion yuan, +8.2%) [2] - The company achieved an outpatient volume of 16.94 million visits and performed 1.29 million surgeries in 2024, marking increases of 12.1% and 9.4%, respectively [3] Financial Projections - The projected earnings per share (EPS) for 2025 and 2026 are 0.44 yuan and 0.50 yuan, respectively, with a net profit forecast of 4.070 billion yuan and 4.649 billion yuan [4] - The company’s gross margin is expected to stabilize around 49.8% in 2025 and improve to 50.1% in 2026 [9] Market Position - The company has established a global medical service network with 974 facilities worldwide, including 811 in mainland China [3] - The overseas revenue reached 2.63 billion yuan in 2024, accounting for 12.5% of total revenue, indicating a growing international presence [3]

Core Viewpoint - The company reported a revenue of 20.98 billion yuan for 2024, with a year-on-year growth of 3.0%, and net profits meeting market expectations. The first quarter of 2025 showed a revenue of 6.03 billion yuan, a year-on-year increase of 16.0%, exceeding market expectations, primarily due to the recovery in consumer business [1]. Group 1: Business Performance - In 2024, the consumer business faced pressure, with refractive and optical revenues growing by 2.3% and 6.4% year-on-year, respectively. However, in Q1 2025, both segments are expected to outperform the overall company revenue growth due to the elimination of price base pressure and the application of new technologies [2]. - The serious medical segment maintained stable growth in 2024, with cataract, anterior segment, and posterior segment revenues increasing by 4.9%, 5.9%, and 8.2% year-on-year, respectively. The company anticipates continued stable performance in Q1 2025 [2]. Group 2: Expansion and Service Improvement - By the end of 2024, the company operated 581 domestic medical institutions and 163 overseas institutions, having acquired nearly 90 domestic medical institutions and the Optimax Group to enter the UK ophthalmology market. This expansion is expected to enhance market positioning and achieve economies of scale [3]. - The company is optimizing service models by extending outpatient hours and building smart hospital platforms to meet diverse patient needs, achieving a patient satisfaction rate close to 99.0% in 2024 [3]. Group 3: Financial Metrics - In 2024, the company reported a gross margin of 48.1%, a sales expense ratio of 10.3%, and a management expense ratio of 14.2%. The net profit margin for the parent company was 16.9% [4]. - In Q1 2025, the company achieved a gross margin of 48.0%, with a reduction in sales and management expense ratios to 9.0% and 12.6%, respectively. The net profit margin for the parent company increased to 17.6% year-on-year [4]. Group 4: Profit Forecast and Valuation - The company adjusted its net profit forecast for 2025-2026 down by 7.73% and 7.94% to 4.09 billion yuan and 4.699 billion yuan, respectively. The current stock price corresponds to a P/E ratio of 29.9x for 2025 and 26.0x for 2026 [5]. - The target price is maintained at 16.0 yuan, corresponding to a P/E ratio of 36.5x for 2025 and 31.8x for 2026, indicating a potential upside of 22.0% from the current stock price [5].

证券代码：301267 证券简称：华厦眼科 华厦眼科医院集团股份有限公司 投资者关系活动记录表 编号：2025-002 | | 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 | | --- | --- | | | □新闻发布会 □路演活动 | | | □现场参观 | | 投资者关系活动类别 | 其他：中金公司、中信建投、中信证券、国泰海通、华泰证 | | | 券、兴业证券、申万宏源、国联民生、西南证券、广发证券、 | | | 华创证券、华安证券、东北证券、招商证券、华福证券、信达 | | | 证券、方正证券、天风证券、民生证券、国盛证券组织的电话 | | | 会议 | | 参与单位名称及人员 | 共计 名投资者参与交流，参会人员名单详见附件。 80 | | 姓名 | | | 时间 | 年 月 日 2025 4 28 15:30-16:30 | | 地点 | 公司会议室 | | | 陈凤国先生 董事 | | | 李晓峰先生 董事、副总经理 | | 上市公司接待人员 姓名 | 张志勇先生 副总经理 | | | 陈鹭燕女士 财务总监 | | | 曹乃恩先生 董事会秘书 | | 投资者关系活动主要 | 一 ...

医药 公 司 报 告 爱尔眼科(300015.SZ) 相关研究报告 【平安证券】爱尔眼科（300015.SZ）*季报点评*具 备经营韧性，静待消费复苏*推荐20241101 证券分析师 叶寅 投资咨询资格编号 S1060514100001 BOT335 事项： 具备经营韧性，25Q1业绩快速增长 推荐 ( 维持) 股价:12.72元 行情走势图 请通过合法途径获取本公司研究报告，如经由未经许可的渠道获得研究报告，请慎重使用并注意阅读研究报告尾页的声明内容 2025年04月25日 公司发布2024年年报以及2025年一季报，2024年收入实现209.83亿元，同比 增长3.02%，归母净利润实现35.56亿元，同比增长5.87%，扣非归母净利润 实现30.99亿元，同比-11.82%。2025Q1公司收入实现60.26亿元，同比增长 15.97%，归母净利润实现10.50亿元，同比增长16.71%，扣非归母净利润实 现10.60亿元，同比增长25.78%。公司拟向全体股东每 10 股派发现金红利 1.6 元（含税）。 平安观点： 研 究 报 告 YEYIN757@pingan.com.cn 倪亦道 投资咨询资格 ...